Fair value (multi-method)
Four independent methods triangulate what RVMD is worth. The headline is the Forward-DCF intrinsic value at a normalized growth rate; the margin of safety compares it to the current price.
Estimated fair value (Forward DCF)
—
Valuation methods
Each method’s implied fair value per share and its upside versus the current price. Missing methods (no analyst coverage, negative earnings, etc.) are shown as “—”.
| Method | Fair value | Upside vs price |
|---|---|---|
| Forward DCF | — | — |
| Exit multiple | — | — |
| Analyst target | $165.33 | +10.79% |
| Graham number | — | — |
- Forward DCF—
- Exit multiple—
- Analyst target$165.33
- Graham number—
Stock price
$149.23
EPS (TTM)
N/A
3Y EPS CAGR
—
Fair value @ hist. growth
—
This analysis is for informational purposes only and is not financial advice. Scenario prices and DCF-style figures depend on your assumptions and data from public filings and estimates. They are not forecasts of future returns.
Reverse DCF did not solve for the current inputs — adjust discount rate, terminal growth, or horizon below.
Model inputs
Move sliders to test how the reverse DCF reacts. Historical-growth markers show where the company has actually grown over the last cycle.
Historical multiples
Each bar is the trailing five-year range (low left, high right). Filled portion runs from low to today; the dot marks today; the small tick marks the five-year median. Low, median, and high are listed under each bar.
Net cash
$225M
Total debt − cash
Beta
1.41
Vs market benchmark
Annual diluted EPS
Per-share earnings by fiscal year — last 3 years anchor the CAGR reference above.
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation